PD-1 Drugs: How Checkpoint Inhibitors Work and What They Treat

What Are PD-1 Drugs?

PD-1 drugs are a class of immunotherapy drugs that block a protein called programmed death-1, or PD-1, found on the surface of T cells. PD-1 is part of the immune system's built-in brakes, a mechanism that normally prevents T cells from attacking healthy tissue. Cancer cells exploit this by displaying molecules called PD-L1, which bind to PD-1 and tell T cells to stand down. PD-1 drugs release those brakes, allowing the immune system to recognize and destroy cancer cells. These drugs are also known as PD-1 checkpoint inhibitors, and they have reshaped treatment across multiple cancer types since the first approval in 2014.

How PD-1 Drugs Work

To understand PD-1 drugs, it helps to think of the immune system as an army with checkpoints. T cells patrol the body for abnormal cells, but PD-1 acts as a safety switch that can order them to halt an attack. Tumors evolve to press that switch by displaying PD-L1 on their surface. PD-1 inhibitors, such as pembrolizumab, nivolumab, cemiplimab, and sugemalimab, bind directly to PD-1 on T cells and prevent PD-L1 from engaging it. With the checkpoint blocked, T cells remain active and can mount a sustained anti-tumor response.

Cancers Treated with PD-1 Drugs

PD-1 drugs are approved for a growing list of cancers, often in combination with chemotherapy, targeted therapy, or other immunotherapies. Common indications include melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, Hodgkin lymphoma, urothelial carcinoma, renal cell carcinoma, hepatocellular carcinoma, and Merkel cell carcinoma. Some PD-1 drugs are also used in specific biomarker-selected populations, such as tumors with high microsatellite instability or mismatch repair deficiency. Treatment decisions depend on cancer type, prior therapies, PD-L1 expression levels, and genomic markers, so a patient's oncologist will weigh these factors when choosing a regimen.

PD-1 Drugs vs. PD-L1 Drugs

PD-1 drugs and PD-L1 drugs both target the same signaling axis but at different points. PD-1 inhibitors bind to the receptor on T cells, while PD-L1 inhibitors, such as atezolizumab, durvalumab, and avelumab, bind to the ligand on tumor or immune cells. In practice, the clinical differences between the two classes are often small, though some studies suggest subtle distinctions in durability of response and side-effect profiles. The choice between a PD-1 and a PD-L1 inhibitor usually depends on the specific cancer, combination strategies, and regulatory approvals for that indication.

Side Effects and Safety Considerations

Because PD-1 drugs unleash the immune system, they can cause immune-related adverse events in which T cells attack healthy organs and tissues. Common side effects include fatigue, skin rash, itching, diarrhea, colitis, hepatitis, thyroid dysfunction, and pneumonitis. More serious but less frequent reactions can affect the lungs, liver, intestines, hormone-producing glands, and kidneys. Most side effects are manageable with corticosteroids or other immunosuppressive agents when caught early, but some can become chronic or life-threatening if not addressed promptly. Patients receiving PD-1 drugs are monitored regularly with blood tests and imaging to detect immune-related toxicities before they escalate.

Response Rates and Durability

PD-1 drugs do not work for everyone, but when they do, responses can be deep and long-lasting. In some cancers, such as melanoma and certain lung cancers, a subset of patients experiences complete remission that persists for years. Biomarkers like PD-L1 expression, tumor mutational burden, and microsatellite instability help predict who is most likely to benefit, though none of these tests are perfect. Ongoing clinical trials continue to refine patient selection and explore combinations that improve response rates while limiting toxicity.

Current and Emerging PD-1 Drugs

Several PD-1 inhibitors are approved globally, and others are in late-stage development. Commonly used agents include pembrolizumab (Keytruda), nivolumab (Opdivo), cemiplimab (Libtayo), and sugemalimab (HiProley). Newer entrants and biosimilars aim to expand access and reduce costs. Researchers are also studying PD-1 drugs in earlier treatment lines, in combination with cancer vaccines, and in tumor types where responses have historically been poor.

What to Expect During Treatment

PD-1 drugs are typically given intravenously every two, three, four, or six weeks, depending on the specific agent and regimen. Treatment can continue for months or years as long as the patient benefits and tolerates the therapy. Regular scans and blood work track tumor response and immune-related side effects. Patients are encouraged to report new symptoms promptly, since early intervention for toxicities often leads to better outcomes. Supportive care, including endocrinology and gastroenterology consultations, may be part of the treatment plan for those on long-term PD-1 therapy.